Breaking News Instant updates and real-time market news.

GPN

Global Payments

$78.99

2.55 (3.34%)

, TSS

TSYS

$48.90

1.71 (3.62%)

12:50
10/05/16
10/05
12:50
10/05/16
12:50

Global Payments higher after beating quarterly expectations, raising guidance

Shares of payment technology company Global Payments (GPN) are advancing after the company reported first quarter financial results that surpassed analysts' expectations. In conjunction with its Q1 earnings report, the company raised its fiscal year 2017 profit view. WHAT'S NEW: Ahead of the market open this morning, Global Payments reported Q1 EPS of 86c on revenue of $817.3M, beating analysts' estimates of 83c and $816.17M, respectively. The company attributed the strong quarterly performance to the acceleration of organic growth and the progress with its Heartland integration efforts. Late last year, Global Payments announced it was acquiring competitor Heartland Payment Systems and the acquisition was completed in late April. "Our fiscal 2017 is off to a terrific start, with organic growth accelerating sequentially across our key markets in the first quarter," said Jeff Sloan, Global Payments' Chief Executive Officer. "Heartland continued its strong growth momentum in the United States. Our businesses in Europe performed exceptionally well, and our Asia business produced its highest rate of organic revenue growth in several quarters." Sloan concluded, "We also could not be more pleased with our Heartland integration efforts, which continue to track ahead of our expectations." WHAT'S NOTABLE: With its quarterly report, the company raised its 2017 EPS view to $3.45-$3.55 from its prior view of $3.40-$3.50. Prior to the earnings report, analysts were expecting $3.47 in EPS. Additionally, the company now sees adjusted operating margin for fiscal 2017 to expand by as much as 50 basis points. Global Payments backed its prior revenue view of $3.2B-$3.3B, or growth of 47% to 52% over fiscal 2016. ANALYST VIEW: On September 15, Goldman Sachs analyst James Schneider upgraded Global Payments to Buy from Neutral saying the company's revenue growth is likely to exceed 10% over the next two years, which is ahead of consensus and management's high-single digit growth target. Cost and revenue synergies from the Heartland acquisition are likely to exceed investor expectations, Schneider told investors in a research note at the time. Schneider raised his price target for the shares to $88 from $80. PRICE ACTION: Shares of Global Payments are up 3.3%, or $2.49, to $78.93. OTHERS TO WATCH: Shares of other publicly traded payment and transaction processing companies that compete with Global Payments include Total System Services (TSS), Fiserv (FISV), First Data (FDC) and Vantiv (VNTV).

GPN

Global Payments

$78.99

2.55 (3.34%)

TSS

TSYS

$48.90

1.71 (3.62%)

FISV

Fiserv

$98.89

-0.86 (-0.86%)

FDC

First Data

$13.38

0.35 (2.69%)

VNTV

Vantiv

$57.00

0.5 (0.88%)

  • 05

    Oct

  • 23

    Oct

GPN Global Payments
$78.99

2.55 (3.34%)

07/22/16
SBSH
07/22/16
NO CHANGE
Target $89
SBSH
Buy
Global Payments price target raised to $89 from $78 at Citi
Citi analyst Ashwin Shirvaikar raised his price target for Global Payments to $89 saying the company is "likely to easily post upside to acquisition synergy assumptions." The analyst likes the stock at these levels and keeps a Buy rating on the name.
07/12/16
DBAB
07/12/16
NO CHANGE
Target $79
DBAB
Buy
Global Payments price target raised to $79 from $72 at Deutsche Bank
Deutsche Bank analyst Bryan Keane raised his price target for Global Payments to $79 saying estimates continue to have an upward bias. The acquisition of Heartland could drive further upside, the analyst contends. He keeps a Buy rating on the shares.
09/15/16
GSCO
09/15/16
UPGRADE
Target $88
GSCO
Buy
Global Payments upgraded to Buy from Neutral at Goldman
Goldman Sachs analyst James Schneider upgraded Global Payments to Buy saying the company's revenue growth is likely to exceed 10% over the next two years, which is ahead of consensus and management's high-single digit growth target. Cost and revenue synergies from the Heartland acquisition are likely to exceed investor expectations, Schneider tells investors in a research note. He upped his price target for the shares to $88 from $80.
08/18/16
OPCO
08/18/16
NO CHANGE
OPCO
Outperform
Oppenheimer encouraged by Global Payments growth opportunity
Following a visit to the company's headquarters, Oppenheimer analyst Glenn Greene says he remains encouraged by Global Payments' intermediate and long-term growth and margin opportunity. The Heartland integration appears ahead of schedule, and the combined entity has already realized sales success, the analyst tells investors in a research note. Further, Greene believes the company's 2017 guidance appears reasonable, if not conservative, and would not preclude upside to its Heartland synergy targets. He reiterates an Outperform rating on the shares.
TSS TSYS
$48.90

1.71 (3.62%)

09/14/16
SBSH
09/14/16
NO CHANGE
SBSH
Citi moves Vantiv up to top pick in processor space
Citi analyst Ashwin Shirvaikar shuffled his rankings in the processor space by moving Vantiv (VNTV) up to his pick from third place. Fidelity National Information (FIS) is his second pick, followed by previous top pick TSYS (TSS) and PayPal (PYPL). Shirvaikar keeps a Buy rating on TSYS but lowered his price target for the shares to $60 from $63. Top-line growth deceleration is happening sooner than expected, the analyst tells investors in a research note.
08/12/16
BARD
08/12/16
UPGRADE
Target $60
BARD
Outperform
TSYS upgraded to Outperform at Baird
As reported previously, Baird analyst David Koning upgraded TSYS to Outperform from Neutral citing the stock's current valuation, the potential for catalysts to eventually play out, and the ability for payment stocks to recover rapidly without near-term catalysts. Baird maintained its $60 price target on TSS shares.
08/12/16
BARD
08/12/16
UPGRADE
Target $60
BARD
Outperform
TSYS upgraded to Outperform from Neutral at Baird
Baird analyst David Koning upgraded TSYS to Outperform citing valuation and maintained its $60 price target.
07/28/16
FANA
07/28/16
UPGRADE
Target $62
FANA
Overweight
TSYS upgraded to Overweight from Equal-Weight at First Analysis
First Analysis analyst Lawrence Berlin upgraded TSYS to Overweight citing the post-earnings selloff and confidence in his 2016 estimates. The analyst has a $62 price target for the shares.
FISV Fiserv
$98.89

-0.86 (-0.86%)

10/04/16
MONN
10/04/16
UPGRADE
MONN
Buy
Fiserv upgraded to Buy from Neutral at Monness Crespi
04/15/16
COMP
04/15/16
INITIATION
Target $85
COMP
Sell
Fiserv initiated with a Sell at Compass Point
Target $85.
03/21/16
OPCO
03/21/16
DOWNGRADE
OPCO
Perform
Fiserv downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Glenn Greene downgraded Fiserv to Perform citing valuation following the recent rally in shares. The analyst continues to have a favorable view of the company's business outlook.
05/09/16
ARGS
05/09/16
UPGRADE
Target $114
ARGS
Buy
Fiserv upgraded to Buy from Hold at Argus
Argus analyst Stephen Biggar upgraded Fiserv to Buy with a $114 price target following the Q1 earnings beat. Operating margins continue to surprise to the upside and expects the company to continue to benefit from secular headwinds, the analyst said.
FDC First Data
$13.38

0.35 (2.69%)

08/31/16
JEFF
08/31/16
INITIATION
Target $16.5
JEFF
Buy
First Data initiated with a Buy at Jefferies
Jefferies analyst Jason Kupferberg started First Data with a Buy rating and $16.50 price target. Growth in the company's domestic merchant processing segment is set to inflect, the analyst tells investors in a research note.
08/31/16
08/31/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BTIG initiated coverage of Juno Therapeutics (JUNO) with a Sell rating, saying the firm is "generally skeptical of current investor expectations for the CD19 CAR T market." The firm has a fair value estimate on Juno of $23 per share. 2. JPMorgan analyst Alex Yao assumed coverage of Sohu.com (SOHU) with an Underweight rating and $40 price target. The rating is unchanged and the price target is lowered from $47. The company will find it difficult to come up with new initiatives to address the continued decline in games revenue, Yao tells investors in a research note. 3. JPMorgan's Yao assumed coverage of SINA (SINA) with an unchanged Overweight rating and $123 price target. 4. Jefferies analyst Jason Kupferberg started First Data (FDC) with a Buy rating and $16.50 price target. Growth in the company's domestic merchant processing segment is set to inflect, the analyst tells investors in a research note. 5. Baird analyst William Power initiated j2 Global (JCOM) with an Outperform rating and $83 price target, citing its attractive valuation, strong free cash flow, consistent margin expansion, the growth in digital media, and its disciplined acquisition strategy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/01/16
BTIG
08/01/16
UPGRADE
BTIG
Buy
First Data upgraded on 2H16 outlook at BTIG
As noted earlier, BTIG upgraded First Data to Buy from Neutral. Following the company's better than expected Q2 results, analyst Mark Palmer thinks the company's turnaround is poised to accelerate in 2H16, driven by benefits from improvements of its North American Global Business Solutions unit. Target $15.
08/30/16
CHLM
08/30/16
INITIATION
Target $20
CHLM
Buy
First Data initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Bradley Berning initiated First Data with a Buy and $20 price target saying the company is in the middle of a turnaround that will accelerate revenue growth and significantly greater earnings growth.
VNTV Vantiv
$57.00

0.5 (0.88%)

10/05/16
10/05/16
DOWNGRADE

Equal Weight
Fifth Third downgraded to Equal Weight at Stephens
As previously reported, Stephens analyst Terry McEvoy downgraded Fifth Third (FITB) to Equal Weight from Overweight on valuation. The analyst now sees the underlying value and capital flexibility from the company's investment in Vantiv (VNTV) as being largely reflected in the stock's valuation and have more comfort in future expense trends. Given the outperformance at Fifth Third, McEvoy believes investors should take profits and move into KeyCorp (KEY).
07/29/16
07/29/16
DOWNGRADE
Target $63

Outperform
Vantiv downgraded to Outperform on moderating outlook at CLSA
As previously reported, CLSA downgraded Vantiv to Outperform from Buy. Analyst Tom McCrohan said Vantiv beat Q2 expectations due to solid Merchant and Financial Institutions segment results, but the back-half of the year will moderate due to factors impacting the Financial Institutions segment, making further multiple expansion difficult.
07/29/16
LYON
07/29/16
DOWNGRADE
LYON
Outperform
Vantiv downgraded to Outperform from Buy at CLSA

TODAY'S FREE FLY STORIES

CME

CME Group

$154.28

2.07 (1.36%)

, GS

Goldman Sachs

$256.12

5.15 (2.05%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Bar Association to hold annual meeting »

Derivatives & Futures…

CME

CME Group

$154.28

2.07 (1.36%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BP

BP

$42.40

-0.5 (-1.17%)

C

Citi

$78.30

0.91 (1.18%)

BAC

Bank of America

$31.72

0.24 (0.76%)

CS

Credit Suisse

$19.06

0.13 (0.69%)

CRL

Charles River

$107.89

1.22 (1.14%)

MS

Morgan Stanley

$57.46

1.62 (2.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 15

    Feb

AMGN

Amgen

$189.28

1.69 (0.90%)

, BAYRY

Bayer

$32.05

0.235 (0.74%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2018 ASCO…

AMGN

Amgen

$189.28

1.69 (0.90%)

BAYRY

Bayer

$32.05

0.235 (0.74%)

BLRX

BioLineRx

$1.09

-0.02 (-1.80%)

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

CELG

Celgene

$102.65

0.93 (0.91%)

DNA

Bought by RHHBY

ESALY

Eisai

$56.88

0.115 (0.20%)

EXEL

Exelixis

$28.00

0.14 (0.50%)

HALO

Halozyme

$17.98

0.13 (0.73%)

INCY

Incyte

$93.16

1.24 (1.35%)

IPSEY

Ipsen

$34.65

0.75 (2.21%)

LXRX

Lexicon

$10.44

0.2 (1.95%)

MGNX

MacroGenics

$19.19

0.3 (1.59%)

MRK

Merck

$61.28

0.15 (0.25%)

NVS

Novartis

$86.94

0.53 (0.61%)

SNY

Sanofi

$44.60

0.09 (0.20%)

ONCY

Oncolytics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 02

    Feb

  • 03

    Feb

  • 05

    Feb

  • 08

    Feb

  • 15

    Feb

  • 16

    Feb

  • 02

    Mar

  • 05

    Mar

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 30

    Apr

  • 02

    May

  • 17

    May

  • 28

    May

  • 23

    Oct

WLFC

Willis Lease

$26.66

0.05 (0.19%)

18:59
01/19/18
01/19
18:59
01/19/18
18:59
Hot Stocks
Willis Lease announces $1,000 bonus for employees »

Willis Lease announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPS

Dr Pepper Snapple

$96.35

1.03 (1.08%)

18:13
01/19/18
01/19
18:13
01/19/18
18:13
Hot Stocks
Dr Pepper to become official sponsor of esports team TSM »

Dr Pepper announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$11.70

0.09 (0.78%)

17:53
01/19/18
01/19
17:53
01/19/18
17:53
Hot Stocks
Vintage Capital in standstill pact with Rent-A-Center »

On January 17, Vintage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AR

Antero Resources

$18.74

-0.59 (-3.05%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Recommendations
Antero Resources analyst commentary at MUFG »

Antero Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.21

0.06 (0.16%)

, TWX

Time Warner

$93.36

0.39 (0.42%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Periodicals
AT&T requesting docs from companies in Time Warner deal hearing, Reuters says »

AT&T (T) is…

T

AT&T

$37.21

0.06 (0.16%)

TWX

Time Warner

$93.36

0.39 (0.42%)

VZ

Verizon

$51.91

0.36 (0.70%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

DISH

Dish

$45.26

0.1 (0.22%)

CHTR

Charter

$366.05

0.8 (0.22%)

DIS

Disney

$110.59

0.17 (0.15%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 08

    Feb

  • 08

    Feb

GRPN

Groupon

$5.57

0.46 (9.00%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Hot Stocks
Groupon announces Chief Product Officer Jay Sullivan resigns »

On January 17, Jay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$102.65

0.93 (0.91%)

17:41
01/19/18
01/19
17:41
01/19/18
17:41
Hot Stocks
Celgene's Abraxane exceeds primary endpoint target in pancreatic cancer trial »

Celgene announced primary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

VALU

Value Line

$19.60

0.3 (1.55%)

17:40
01/19/18
01/19
17:40
01/19/18
17:40
Hot Stocks
Value Line reaffirms $3M stock repurchase program »

The Board of Directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALU

Value Line

$19.60

0.3 (1.55%)

17:39
01/19/18
01/19
17:39
01/19/18
17:39
Hot Stocks
Value Line declares special dividend of 20c per share »

Payable on March 9 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZEAL

Zealand Pharma

$15.05

-0.78 (-4.93%)

17:34
01/19/18
01/19
17:34
01/19/18
17:34
Hot Stocks
Zealand Pharma: FDA approves IND for Phase 3 trials of dasiglucagon in CHI »

The U.S. FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMSF

Genmab

$190.75

2.75 (1.46%)

, JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

17:29
01/19/18
01/19
17:29
01/19/18
17:29
Hot Stocks
Genmab says FDA grants priority review for daratumumab »

Genmab (GNMSF) announced…

GNMSF

Genmab

$190.75

2.75 (1.46%)

JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

HII

Huntington Ingalls

$242.12

5.24 (2.21%)

17:21
01/19/18
01/19
17:21
01/19/18
17:21
Hot Stocks
Huntington Ingalls awarded $125.2M government contract modification »

Huntington Ingalls Inc. -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 21

    Feb

BAESY

BAE Systems

$33.30

0.18 (0.54%)

, GD

General Dynamics

$209.10

1.3 (0.63%)

17:20
01/19/18
01/19
17:20
01/19/18
17:20
Hot Stocks
BAE Systems, General Dynamics awarded $237.6M government contract modification »

BAE Systems (BAESY) San…

BAESY

BAE Systems

$33.30

0.18 (0.54%)

GD

General Dynamics

$209.10

1.3 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

SYRS

Syros Pharmaceuticals

$10.80

0.27 (2.56%)

17:17
01/19/18
01/19
17:17
01/19/18
17:17
Syndicate
Breaking Syndicate news story on Syros Pharmaceuticals »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTFC

Wintrust Financial

$87.81

0.96 (1.11%)

17:13
01/19/18
01/19
17:13
01/19/18
17:13
Hot Stocks
Wintrust Financial raises its minimum wage to $15 per hour »

Wintrust Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TWTR

Twitter

$23.66

-0.38 (-1.58%)

17:07
01/19/18
01/19
17:07
01/19/18
17:07
Hot Stocks
Twitter says has identified more IRA and automated Russia-based accounts »

In a statement on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

ITEK

Inotek Pharmaceuticals

17:04
01/19/18
01/19
17:04
01/19/18
17:04
Hot Stocks
Boxer Capital reports 5.3% passive stake in Rocket Pharmaceuticals »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OIS

Oil States

$32.80

0.35 (1.08%)

17:03
01/19/18
01/19
17:03
01/19/18
17:03
Syndicate
Breaking Syndicate news story on Oil States »

Oil States files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVGO

Broadcom

$266.39

-3.41 (-1.26%)

, QCOM

Qualcomm

$68.04

-0.01 (-0.01%)

16:43
01/19/18
01/19
16:43
01/19/18
16:43
Hot Stocks
Broadcom receives second request from FTC for proposed Qualcomm deal »

Broadcom (AVGO) announced…

AVGO

Broadcom

$266.39

-3.41 (-1.26%)

QCOM

Qualcomm

$68.04

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

TRNC

tronc

$19.53

0.3 (1.56%)

16:37
01/19/18
01/19
16:37
01/19/18
16:37
Periodicals
LA Times' CEO Ross Levinsohn to take leave of absence amid probe, WSJ says »

Ross Levinsohn, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AP

Ampco-Pittsburgh

$14.20

0.15 (1.07%)

16:35
01/19/18
01/19
16:35
01/19/18
16:35
Syndicate
Breaking Syndicate news story on Ampco-Pittsburgh »

Ampco-Pittsburgh files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

CG

Carlyle Group

$24.35

-0.05 (-0.20%)

, UBSH

Union Bankshares

$38.79

0.54 (1.41%)

16:33
01/19/18
01/19
16:33
01/19/18
16:33
Hot Stocks
Carlyle Group reports 6% passive stake in Union Bankshares »

In a regulatory filing,…

CG

Carlyle Group

$24.35

-0.05 (-0.20%)

UBSH

Union Bankshares

$38.79

0.54 (1.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

ANDX

Andeavor Logistics

$52.52

0.12 (0.23%)

16:31
01/19/18
01/19
16:31
01/19/18
16:31
Hot Stocks
Andeavor Logistics raises quarterly cash distribution to $1.00 per unit »

The fourth quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.